Ferring and Enteris BioPharma to develop new oral peptide therapy

Ferring Pharmaceuticals has announced a new drug development partnership with Enteris BioPharma.

The licence agreement will leverage Enteris' proprietary, patented oral peptide and small molecule delivery platform Peptelligence to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring.

Under the terms of the deal, Enteris will license its oral drug delivery technologies to Ferring, as well as providing products that have completed clinical trials, in exchange for milestone-based fees and royalties.

The Peptelligence platform has proven effective over the last decade in enabling the safe delivery of peptide-based therapeutics and other molecules with low oral bioavailability. It is hoped that this work will facilitate the oral delivery of medications that must otherwise be administered by injection.

Alan Harris, senior vice-president for research and development at Ferring Pharmaceuticals, said: "The ability to deliver oral peptides offers Ferring the opportunity to provide additional therapeutic choices to patients. We are impressed with Enteris' proprietary oral delivery technology and look forward to working with them to advance this development programme."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.